FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283711820> ?p ?o ?g. }

• W4283711820 endingPage "665" @default.
• W4283711820 startingPage "665.2" @default.
• W4283711820 abstract "Background Fatigue is a major complaint in primary Sjögren’s syndrome (pSS). The importance of fatigue in pSS is demonstrated by its inclusion as one of the three domains of the EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) as well as being the primary outcome measure of a large clinical trial. 1 To date, there is no effective treatment for fatigue and more fundamental studies are needed to identify potential targets for therapy. In a conceptual framework, fatigue is defined as a self-reported symptom derived from two attributes: performance fatigability and perceived fatigability (Figure 1). Figure 1. Conceptual framework (adapted from Enoka) 2 Objectives To acquire a better understanding of fatigue in pSS, we investigated objective measures of performance decline and evaluated the relation of self-reported fatigue with performance fatigability and factors modulating perceptions of fatigability. Methods 39 pSS patients and 27 healthy controls were included. To assess performance fatigability, force decline was measured during a sustained (124s) maximal voluntary contraction (MVC) with the index finger abductor muscle, and voluntary muscle activation was indexed using peripheral nerve stimulation superimposed on maximal voluntary contractions. Self-reported fatigue was quantified using the Fatigue Severity Scale (FSS) and Modified Fatigue Impact Scale (MFIS). Pain, depression, and anxiety were assessed using questionnaires and serological inflammatory markers were measured in serum as factors relating to perceived fatigability. Results Self-reported fatigue was significantly higher in pSS than controls (FSS: 4.8 vs. 2.3, p<0.001); 67% of patients and no controls reported significant fatigue (FSS>4). Mean voluntary muscle activation was reduced in pSS compared to controls (81.5% vs. 87.8%, p=0.030). Force decline during the sustained MVC did not differ between groups (60.6% vs. 63.1%, p=0.246). MFIS physical was positively associated with symptoms (ESSPRI pain: ρ=0.51, HADS depression: ρ=0.45 and HADS anxiety: ρ=0.29) and negatively associated with serological inflammatory markers (MxA: ρ=-0.49 and CXCL10: ρ=-0.37). Multivariable linear regression showed that force decline, pain and depression were associated with the MFIS physical domain in pSS (total explained variance of 47%). The inclusion of serological inflammatory markers did not help to explain more variance in this model. Conclusion This study demonstrates that performance fatigability in pSS was compromised by a reduced capacity of the central nervous system to drive the muscle. Furthermore, self-reported fatigue is a multifactorial symptom associated with both performance fatigability and perceived fatigability in patients with pSS. References [1]Bowman et al. Arthritis Rheumatol. 2017;69, 1440–50. [2]Enoka and Duchateau. Med. Sci. Sports Exerc. 2016;48,2228–38. Disclosure of Interests Roeland Prak: None declared, Suzanne Arends: None declared, Gwenny M. Verstappen: None declared, Greetje S. van Zuiden: None declared, Frans G.M. Kroese: None declared, Hendrika Bootsma Speakers bureau: Bristol Myers Squibb, Novartis, Consultant of: Bristol Myers Squibb, Roche, Novartis, Medimmune, Union Chimique Belge, Grant/research support from: Bristol Myers Squibb, Roche, Inge Zijdewind: None declared" @default.
• W4283711820 created "2022-06-30" @default.
• W4283711820 creator A5003351839 @default.
• W4283711820 creator A5022628690 @default.
• W4283711820 creator A5028063648 @default.
• W4283711820 creator A5031351999 @default.
• W4283711820 creator A5034427430 @default.
• W4283711820 creator A5038644871 @default.
• W4283711820 creator A5056288853 @default.
• W4283711820 date "2022-05-23" @default.
• W4283711820 modified "2023-10-01" @default.
• W4283711820 title "POS0758 REDUCED CENTRAL NERVOUS SYSTEM DRIVE IN PRIMARY SJÖGREN’S SYNDROME IS ASSOCIATED WITH OBJECTIVE DECLINE IN MOTOR PERFORMANCE AND SELF-REPORTED FATIGUE" @default.
• W4283711820 doi "https://doi.org/10.1136/annrheumdis-2022-eular.2933" @default.
• W4283711820 hasPublicationYear "2022" @default.
• W4283711820 type Work @default.
• W4283711820 citedByCount "0" @default.
• W4283711820 crossrefType "journal-article" @default.
• W4283711820 hasAuthorship W4283711820A5003351839 @default.
• W4283711820 hasAuthorship W4283711820A5022628690 @default.
• W4283711820 hasAuthorship W4283711820A5028063648 @default.
• W4283711820 hasAuthorship W4283711820A5031351999 @default.
• W4283711820 hasAuthorship W4283711820A5034427430 @default.
• W4283711820 hasAuthorship W4283711820A5038644871 @default.
• W4283711820 hasAuthorship W4283711820A5056288853 @default.
• W4283711820 hasBestOaLocation W42837118201 @default.
• W4283711820 hasConcept C118552586 @default.
• W4283711820 hasConcept C126322002 @default.
• W4283711820 hasConcept C139719470 @default.
• W4283711820 hasConcept C162324750 @default.
• W4283711820 hasConcept C1862650 @default.
• W4283711820 hasConcept C2776867660 @default.
• W4283711820 hasConcept C2777831278 @default.
• W4283711820 hasConcept C2779566273 @default.
• W4283711820 hasConcept C3020395016 @default.
• W4283711820 hasConcept C558461103 @default.
• W4283711820 hasConcept C71924100 @default.
• W4283711820 hasConcept C99508421 @default.
• W4283711820 hasConceptScore W4283711820C118552586 @default.
• W4283711820 hasConceptScore W4283711820C126322002 @default.
• W4283711820 hasConceptScore W4283711820C139719470 @default.
• W4283711820 hasConceptScore W4283711820C162324750 @default.
• W4283711820 hasConceptScore W4283711820C1862650 @default.
• W4283711820 hasConceptScore W4283711820C2776867660 @default.
• W4283711820 hasConceptScore W4283711820C2777831278 @default.
• W4283711820 hasConceptScore W4283711820C2779566273 @default.
• W4283711820 hasConceptScore W4283711820C3020395016 @default.
• W4283711820 hasConceptScore W4283711820C558461103 @default.
• W4283711820 hasConceptScore W4283711820C71924100 @default.
• W4283711820 hasConceptScore W4283711820C99508421 @default.
• W4283711820 hasIssue "Suppl 1" @default.
• W4283711820 hasLocation W42837118201 @default.
• W4283711820 hasOpenAccess W4283711820 @default.
• W4283711820 hasPrimaryLocation W42837118201 @default.
• W4283711820 hasRelatedWork W1848615917 @default.
• W4283711820 hasRelatedWork W2006337105 @default.
• W4283711820 hasRelatedWork W2054295681 @default.
• W4283711820 hasRelatedWork W2057351471 @default.
• W4283711820 hasRelatedWork W2165369897 @default.
• W4283711820 hasRelatedWork W2266838892 @default.
• W4283711820 hasRelatedWork W2331338136 @default.
• W4283711820 hasRelatedWork W2856569808 @default.
• W4283711820 hasRelatedWork W2894568037 @default.
• W4283711820 hasRelatedWork W4302974635 @default.
• W4283711820 hasVolume "81" @default.
• W4283711820 isParatext "false" @default.
• W4283711820 isRetracted "false" @default.
• W4283711820 workType "article" @default.